|Dr. Jeffrey M. Jonas||CEO, Pres & Director||983.77k||N/A||1953|
|Ms. Kimi E. Iguchi||CFO & Treasurer||536.37k||2.7M||1962|
|Mr. Michael Cloonan||Chief Operating Officer||582.75k||2.54M||1971|
|Ms. Anne Marie Cook||Sr. VP, Gen. Counsel & Sec.||564.84k||2.14M||1962|
|Dr. Stephen J. Kanes||Chief Medical Officer||580.67k||973.02k||1965|
|Dr. Heinrich Schlieker Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Dr. Albert J. Robichaud||Chief Scientific Officer||N/A||N/A||1961|
|Mr. Matthew Calistri||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Erin E. Lanciani||Sr. VP of People & Organizational Strategy||N/A||N/A||1969|
|Dr. Amy Schacterle||Sr. VP of Global Regulatory Affairs & Policy||N/A||N/A||N/A|
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.